A higher percentage of MMR-proficient tumors with BRAF ( V600E ) were proximal ( 76 % ) , high-grade ( 44 % ) , N2 stage ( 59 % ) , and detected in women ( 59 % ) , compared with MMR-proficient tumors without BRAF ( V600E ) or KRAS mutations ( 33 % , 19 % , 41 % , and 42 % , respectively ; all P < .0001 ) .